Introduction

Rhumbline Advisers – a prominent institutional investor – recently boosted its stake in Avidity Biosciences (NASDAQ: RNA) to holdings worth about $4.86 million (^[1]). This stake, representing roughly 0.14% of Avidity’s shares, signals Rhumbline’s exposure to Avidity’s potential. Avidity Biosciences is a clinical-stage biotech pioneering RNA therapeutics, and Rhumbline’s bet raises the question: should investors follow suit or steer clear? In this report, we dive into Avidity’s business fundamentals – its pipeline, financials, leverage, valuation, and key risks – to help weigh whether to be “in or out” alongside Rhumbline.

Company & Pipeline Overview

Avidity Biosciences is developing a new class of RNA medicines called Antibody-Oligonucleotide Conjugates (AOCs), which combine antibody targeting with precise RNA-based payloads (^[2]). The company’s pipeline currently features three programs tackling rare muscle disorders:

– Delpacibart etedesiran (AOC 1001) for myotonic dystrophy type 1 (DM1) – now in a Phase 3 trial (HARBOR) (^[2]). This program has Fast Track and Orphan Drug designations, and in October 2024 the FDA lifted a prior partial clinical hold after safety data allowed expansion of high-dose cohorts (^[3]) (^[4]). – Delpacibart braxlosiran (AOC 1020) for facioscapulohumeral muscular dystrophy (FSHD) – in Phase 1/2 (FORTITUDE) with biomarker data showing >50% DUX4 gene reduction and encouraging safety (^[2]). This could become the first approved therapy for FSHD if successful. – Delpacibart zotadirsen (AOC 1044) for Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) – in Phase 1/2 (EXPLORE44) with an open-label extension. Early data showed a 25% increase in dystrophin production and favorable tolerability (^[5]). Avidity plans to file a BLA (FDA approval application) for this DMD program by the end of 2025 (^[5]).

Notably, Avidity has attracted Big Pharma partnerships that validate its platform and provide non-dilutive funding. In 2019, Eli Lilly paid $20 million upfront for rights to develop AOCs in immunology, and Avidity could earn up to ~$405 million per target in milestones plus royalties (^[2]). More recently in late 2023, Bristol Myers Squibb paid $100 million upfront (including a $40 million equity investment) to collaborate on AOCs for cardiology targets (^[2]). That BMS deal carries over $2.17 billion in potential milestone payouts plus high-single to low-double-digit royalties if programs succeed (^[2]) (^[2]). These partnerships underscore the promise of Avidity’s technology while also contributing to its cash reserves.

It’s important to note that Avidity remains pre-revenue from product sales – as is typical for a biotech at this stage. Since its 2012 inception, the company has focused on R&D and has no approved products on the market (^[2]). Any meaningful revenue today comes only from collaboration payments (about $10.9 million in 2024) (^[5]). Meanwhile, expenses are heavy: Avidity’s net loss in 2024 was over $322 million (^[2]) due to intensive R&D spending. In short, investors are valuing Avidity based on its pipeline potential and scientific progress, rather than current earnings.

Dividend Policy & Shareholder Yield

Avidity Biosciences does not pay any dividend and has no history of ever declaring cash dividends (^[6]). All available capital is reinvested into drug development – sensible for a company with negative earnings and high cash needs. The dividend yield stands at 0%, and there is no expectation of near-term dividends given the lack of profits and the pressing funding requirements of clinical trials. In essence, shareholders’ potential “yield” on this stock would come from capital appreciation if the company’s drug candidates succeed, not from any ongoing income distribution. (Metrics like AFFO/FFO are not applicable outside of real estate, so for Avidity the focus is on R&D spending and cash burn rather than funds-from-operations.)

Financial Position: Cash Burn & Runway

Cash Burn: As a development-stage biotech, Avidity runs significant operating losses funded by external capital. In 2024, R&D expenses were ~$303.6 million – a jump of 59% from 2023 as multiple trials advanced (^[5]). The company reported a net loss of $322.3 million for 2024 (^[2]) and continues to log negative earnings per share (for example, –$0.80 EPS in the last quarter of 2024, with a net profit margin of –2772%!) (^[7]). These staggering negative margins reflect the reality that Avidity’s minimal collaboration revenue covers only a tiny fraction of its R&D and administrative costs. However, such losses are expected at this stage – essentially, the company is “burning cash” to create future value in the form of drug data and intellectual property.

$Bill O\$

“The only company I recommend for your Gold & Silver needs is American Hartford Gold.”
— Bill O'Reilly

See How It Works

Cash Runway: The good news is that Avidity has amassed a very large cash reserve to fund this burn. As of December 31, 2024, the company held approximately $1.5 billion in cash, cash equivalents, and marketable securities (^[5]). This war chest was bolstered by a sizable follow-on equity offering in August 2024 and the $100 million upfront from BMS, among other fundraising moves. According to management, this “strong balance sheet with ~$1.5 billion” allows Avidity to continue building out its organization and supports its plans through at least the next year (^[5]). In fact, the 2024 annual report stated that existing cash is sufficient to fund operations for at least 12 months beyond the 10-K filing (i.e. into early 2026) (^[2]). Based on the current ~$300 million+ annual spend rate, that implies roughly 4–5 years of runway – although burn may increase as trials progress or if commercial launch preparations accelerate. For now, Avidity is well-capitalized and not under imminent pressure to raise additional funds, a notable advantage in a volatile biotech funding environment.

It’s worth noting that Avidity’s cash inflows so far have come from issuing equity and collaboration payments rather than debt. This strategy avoids interest costs but does result in share dilution. The company’s outstanding shares have grown from ~37.5 million at IPO in mid-2020 to about 119 million shares by late 2024 (^[6]). For existing shareholders, each financing round means owning a smaller slice of the pie; however, if the capital raised significantly increases the pie’s future value (by enabling drug approvals), the dilution can be worthwhile. Investors should be mindful that Avidity may continue to tap equity markets or partners for funding if trials take longer or new opportunities arise – though management has signaled confidence in its current cash runway.

Leverage & Debt Obligations

Avidity Biosciences carries virtually no debt on its balance sheet. The company has financed its growth almost entirely with equity and partnership capital, resulting in minimal leverage. As of year-end 2024, total liabilities were only $139 million, chiefly consisting of deferred revenue (upfront payments from Lilly/BMS that are recognized over time) and lease obligations – not traditional bank debt (^[5]) (^[5]). The long-term lease liabilities were under $3 million (^[5]), and there are no outstanding loans or bonds coming due. In other words, Avidity has no significant debt maturities to worry about, and interest expense is negligible.

Limited Time · 97% OFF

The #1 Crypto to “Buy the Dip” With Right Now

Hot altcoin recommendation by Bryce Paul — guide NOW just $3 (normally $97)

Reveal My #1 Altcoin →

Instant access • 90-day refund • Mobile-friendly guide

Save 97%

This clean balance sheet gives Avidity financial flexibility. It isn’t burdened by interest payments and covenants, so essentially every dollar of cash can go into R&D and building the business. The flip side is that equity holders bear all the risk (since there are no creditors), and dilution has been the funding mechanism as noted. But from a solvency perspective, the company is in a net cash position – its $1.5 billion cash stockpile far exceeds total liabilities (^[5]) (^[5]). Such low leverage is common for early biotech firms and means Avidity can withstand setbacks without facing bankruptcy risk from debt. There is also untapped capacity to take on debt in the future if needed (for example, some commercial-stage biotechs later arrange credit lines), but given the cash balance, that seems unnecessary in the near term. Overall, Avidity’s financial position is robust and not reliant on borrowing – a reassuring sign for a high-risk venture.

With no debt and no dividends, traditional coverage ratios (like interest coverage or dividend coverage) aren’t relevant here. The most critical “coverage” metric for Avidity is whether its cash covers its operational needs, which, as discussed, appears to be the case for the next few years barring unexpected events.

Valuation & Investor Sentiment

Market Valuation: Avidity’s stock currently trades on future potential rather than current earnings, so valuation metrics require some interpretation. At around $30–31 per share in mid-2025, the company’s market capitalization is roughly $3.5–3.8 billion (^[1]). With ~$1.5 billion in cash on hand, the enterprise value (EV) – which reflects the market’s valuation of the business’s operations/pipeline – is about $2.0–2.3 billion. This means nearly 40% of Avidity’s market cap is backed by cash on the balance sheet (^[5]) (^[1]). The stock’s price-to-book ratio (market value vs. $1.42B equity) is ~2.5x, indicating investors are valuing the company at a premium to its accounting assets, presumably for its intellectual property and drug prospects.

Traditional multiples like P/E or PEG are not meaningful since Avidity has negative earnings. (For reference, the trailing PE is around –11 based on a ~$2.90 per share annual loss (^[1]).) Price-to-sales is astronomically high given only ~$11M in 2024 revenue. Such ratios underscore that Avidity’s valuation is based on pipeline promise: investors are effectively pricing in the probability-weighted future sales of its potential drugs. If Avidity’s therapies for DM1, DMD, and FSHD eventually reach the market, annual revenues could be in the hundreds of millions (given rare disease drug pricing). The current EV of ~$2.2B can be viewed relative to those future opportunities – for example, is it reasonable for three first-in-class rare disease drugs to collectively generate well above $2B in value? Bulls argue yes, especially since DM1 and FSHD have no existing treatments (allowing high pricing power), while DMD is a large orphan market where new therapies are in demand. Bears counter that everything still has to go right in trials and approvals for any revenue to materialize.

Institutional Ownership: It’s notable that Avidity’s shareholder base includes several respected biotech-focused funds, indicating specialist investor confidence. For instance, RA Capital Management holds ~6.3 million shares (nearly $290M worth as of late 2024) (^[7]), and Avoro Capital held ~7.5 million shares (~$218M worth) after adding to its position in Q4 2024 (^[1]). Wellington Management and Janus Henderson have each amassed 7–8 million shares as well (^[1]). These large positions by sector-focused institutions suggest that knowledgeable investors see Avidity as one of the more promising players in RNA therapeutics. Their presence can be a positive signal – though not a guarantee – and it provides some validation beyond Rhumbline’s smaller, index-driven stake. On the flip side, concentrated ownership by a few funds can add volatility (if one decides to unload shares).

Analyst Coverage: Wall Street analysts appear to be broadly bullish on Avidity. According to recent surveys, around ten analysts cover RNA stock and all have “Buy” ratings, with a consensus price target in the mid-$60s per share (^[7]). For example, firms like HC Wainwright, Chardan, Needham, Bank of America, and JPMorgan have issued positive outlooks, with individual price targets ranging from roughly $54 up to $75 (^[1]). These targets imply optimism that the stock could double from recent levels if the company executes well. Analysts have cited Avidity’s first-mover advantage in AOC technology and the sizeable patient populations in its rare disease focus (~40,000 DM1 patients in the U.S., ~16,000 FSHD patients, etc.) as supporting a multi-billion dollar revenue potential in the long term. Of course, analyst targets often assume successful trial outcomes. It’s also worth noting that the stock hit a 52-week high of $56 already during 2024, before pulling back to the $30 range (^[7]) – reflecting how quickly sentiment (and valuation) can swing on clinical news in this name.

Stock Performance: Avidity’s share price has been volatile, typical for biotech. Over the past year it traded as low as $14.75 and as high as $56.00, a >3x move between extremes (^[7]). Positive clinical readouts and partnership news in 2023 propelled the stock higher, while broader market rotations out of biotech or profit-taking have caused retreats. The stock’s beta is ~1.0 (^[7]), suggesting volatility roughly in line with the market, but that belies the dramatic biotech-specific moves seen around catalysts. Investors should be prepared for continued price swings as Avidity approaches major milestones (detailed below). In essence, the market is pricing in a significant probability of success – but also some risk discount – and that price will update in real-time with each data release.

Risks, Red Flags, and Challenges

For all its promise, Avidity Biosciences carries substantial risks that prospective investors must weigh. This is a high-reward but high-risk equity. Key risks and potential red flags include:

– Clinical & Regulatory Uncertainty: All of Avidity’s product candidates must successfully complete clinical trials and obtain regulatory approvals – a process with no guarantees. The science is unproven in humans at large scale, and Avidity acknowledges that its novel AOC platform “may not produce any products of commercial value” (^[5]) if results disappoint. Efficacy that looked encouraging in early cohorts must be confirmed in larger Phase 3 trials, and there’s a risk that pivotal studies fail to meet endpoints or reveal new issues. Even if some endpoints are met, regulators might require additional data. In short, the company could spend years (and hundreds of millions of dollars) only to have a drug candidate fail or face rejection – which would severely hurt the stock.

– Safety Risks: As a therapy that intervenes at the genetic/molecular level, safety will be closely scrutinized. A vivid example was the FDA’s partial clinical hold on AOC 1001 for DM1 in late 2022 after a patient experienced a serious adverse event at the high dose (^[4]). While that hold was fully lifted by October 2024 after safety monitoring and FDA consultation (^[3]), the incident highlights the potential for unexpected side effects to derail development. Going forward, larger patient exposures might reveal side effects not seen in small trials. Any new safety signal (e.g. liver toxicity, immune reactions, etc.) could lead regulators to pause trials again or demand extensive additional studies. Importantly, other cutting-edge neuromuscular therapies have hit safety snags too – for instance, Sarepta’s gene therapy for DMD (Elevidys) was recently halted for investigation after patient deaths (^[8]). This underscores that the path to treating these diseases is risky, and Avidity’s drugs will be no exception in needing careful safety evaluation.

– Competition & Market Adoption: Avidity aims to be first-to-market in DM1 and FSHD, but it won’t be alone for long if it succeeds. For DMD, the competitive landscape is already taking shape – gene therapy (Sarepta’s Elevidys) has been approved for young DMD patients (^[9]), and other exon-skipping or gene-editing approaches are in development. In June 2024, the FDA also approved an HDAC inhibitor (Italfarmaco’s givinostat) for DMD, which treats all genetic variants, indicating new rivals emerging (^[10]). While none of these directly duplicate Avidity’s approach, they could slice into the addressable market or set a high bar for efficacy. Moreover, if Avidity’s drugs reach market, their adoption will depend on persuading physicians and insurers of their value. Payer dynamics pose a risk – for example, gene therapies for rare diseases have multi-million dollar price tags (^[11]), and insurers may balk at covering new high-cost treatments without clear superiority. Avidity will need to demonstrate not just clinical benefit but also cost-effectiveness or unique value (especially if its therapies require ongoing dosing rather than one-shot cures). The open question is whether AOC drugs will be seen as breakthrough enough in real-world use to command premium pricing and broad uptake.

– Cash Burn & Dilution: Although Avidity is well-funded now, its cash burn is very high and likely to continue or increase as Phase 3 trials and commercialization prep ramp up. If timelines extend or additional trials are required, the company could eventually “exhaust its available capital resources sooner than…expected” (^[5]), potentially forcing new funding rounds. That could mean issuing more equity (diluting existing shareholders further) or taking on debt or partnering away rights to raise cash. For context, Avidity’s share count jumped by ~60% in 2024 alone (^[6]), and future dilution remains a risk if the company spends more than anticipated. An investor in RNA stock should be comfortable with the possibility of secondary offerings or other financing that might pressure the stock price. The upside is that Avidity currently has a multi-year runway, but prudent investors will monitor the burn rate relative to the cash pile every quarter.

– Execution & Commercialization Risks: Avidity is still essentially a research organization and has never launched a commercial product. If its drug approvals come to fruition around 2025–2026, the company plans to transition into a commercial-stage entity, including building a sales and marketing infrastructure (^[5]). This leap introduces execution risk – excelling in science does not guarantee success in drug launch and sales. Management will need to hire and train a specialized rare-disease sales force, navigate supply chain and manufacturing at scale, and engage with patient advocacy and reimbursement processes. Any stumbles in launch strategy (e.g. failing to educate physicians, or pricing missteps) could limit the revenue uptake even if the drugs are good. Investors should watch how the company prepares for commercialization over the next 18 months. Sometimes small biotechs choose to partner or be acquired rather than go it alone for launches – whether Avidity will seek a commercial partner (especially overseas) is an open question. Until we see execution, there’s a risk that the company’s inexperience in marketing could hamper its otherwise strong scientific story.

– Insider Selling & Ownership: It’s worth noting that some insiders have been selling shares, which can be seen as a yellow flag. In the last quarter of 2024, insiders (including the CEO and other officers) sold around 129,000 shares of Avidity – over $4.2 million worth of stock – as the share price rallied (^[7]). Insiders still retain about 3.7% of the company, meaning they do have skin in the game, but the recent sales indicate that even those closest to the company saw fit to take some profit off the table. While insider selling may occur for many reasons (diversification, personal finance, scheduled plans), investors often prefer to see insiders accumulating or holding, especially ahead of major milestones. This insider activity doesn’t by itself undermine the investment case, but it’s something to keep an eye on.

In sum, Avidity faces the standard biotech risks of trial failure, regulatory hurdles, high cash burn, and future competition – perhaps amplified by the novelty of its RNA-conjugate platform. The company itself candidly lists these risk factors in its SEC filings, noting the possibility of delays in trials, reliance on third parties, inability to realize benefits from collaborations, and numerous factors outside its control that could impede success (^[5]) (^[5]). Any investor considering joining Rhumbline in betting on RNA stock must be comfortable with these uncertainties and the very real chance of setbacks.

Open Questions & Outlook – Are You In or Out?

With Rhumbline’s position established and Avidity’s situation laid out, the decision for investors boils down to confidence in Avidity’s story versus tolerance for its risks. A few open questions could determine whether this bet pays off or not:

– Can Avidity deliver pivotal trial success? The next 12–18 months will be crucial. By mid-2025, the Phase 3 DM1 trial (HARBOR) is expected to complete enrollment, and by late 2025 Avidity aims to file for approval of its DMD drug. How those trials read out will likely make or break the company’s value. Positive Phase 3 results or a smooth BLA filing could validate the platform and significantly de-risk the story – whereas a trial failure would be a major setback. Investors must gauge the likelihood of these outcomes based on early data (so far largely positive) and the soundness of the science.

– Will the safety profile hold up in larger populations? The easing of the FDA hold and the generally favorable safety reported in current studies (^[5]) (^[5]) are encouraging, but only a few dozen patients have been dosed so far. As trials expand into hundreds of patients, will any serious adverse events emerge? The answer will affect regulators’ stance and physicians’ willingness to prescribe AOC therapies. This is an area to watch closely – any sign of safety troubles could quickly turn sentiment negative again, as was seen temporarily in 2022.

– How big is the commercial opportunity, really? While Avidity’s target diseases are rare, they are not tiny niches – and with no existing treatments, the unmet medical need is high. If Avidity’s drugs work as hoped, uptake could be rapid among eligible patients. However, key questions remain on pricing and payer acceptance. For instance, will Avidity price its therapies in line with other orphan drugs (potentially hundreds of thousands per patient annually, or a multi-million dollar one-time cost)? And will insurers cover them without onerous hurdles? The outcomes here will determine if Avidity can translate clinical success into significant revenue and earnings. Optimistically, being first to market in DM1/FSHD could allow Avidity to define the standard of care (and justify premium pricing), but these assumptions will be tested when the company eventually engages with health systems and payers.

– Is management up to the task of scaling up? Thus far, Avidity’s team has executed well on research, securing partnerships and hitting trial milestones. The leadership (CEO Sarah Boyce and others) bring experience from major biotech/pharma companies, which bodes well (^[7]). Yet launching multiple products globally is a massive undertaking for a company of this size. Can Avidity build a commercial organization to simultaneously support DM1, DMD, and FSHD launches (potentially staggered over 2026–2027)? Will they need to partner ex-US or on certain functions to succeed? Investors will look for signals in 2025 of how commercialization strategy is shaping up – hires, early market education initiatives, etc. The answer will influence whether Avidity can evolve into a standalone biopharma company or perhaps become a buyout target for a larger player seeking to commercialize the AOC platform.

Ultimately, “Are you in or out?” comes down to your risk appetite and conviction in Avidity’s platform. Rhumbline’s ~$4.86M position is relatively small and likely part of a broad index strategy (^[1]), meaning even they are not making an outsized active bet. In contrast, specialized biotech funds with deep knowledge have made sizable bets on Avidity (^[1]), reflecting genuine enthusiasm for its prospects. If you believe that Avidity’s AOCs could become breakthrough treatments for currently untreatable diseases – and you’re willing to endure volatility – then being “in” this stock ahead of the crowd could yield significant rewards. The company’s ample cash and big-pharma validation provide a cushion and credibility that many small biotechs lack.

On the other hand, if you are risk-averse or skeptical, you might stay “out” until more proof arrives. There is no shame in waiting for Phase 3 data; yes, the stock might jump if results are great, but waiting reduces the chance of being caught by a devastating failure. The current valuation, while not extreme given the cash, already anticipates success to some degree – meaning downside could be sharp if the narrative falters. An investor on the sidelines can always choose to invest later, even at higher prices, once the path to approval (and revenue) is clearer. Remember, even approved drugs must prove commercially viable; some investors may prefer to see initial launch traction before getting on board.

In conclusion, Avidity Biosciences offers a high-risk/high-reward proposition in the biotech arena. Rhumbline’s bet signals confidence in the long run, but each investor must answer for themselves whether the potential payoff justifies the uncertainties. As the saying goes in biotech: “Invest only what you can afford to lose.” With milestone data on the horizon, we will soon learn if Avidity’s RNA revolution progresses as hoped. Are you in or out? The choice, and the risk, is yours. (^[5])

Sources

For informational purposes only; not investment advice.